HMGB1/Bcl-2表达与结直肠癌患者化疗耐药及预后关系的研究  

Impact of HMGB1 expression and Bcl-2 expression on chemoresistance and prognosis in colorectal cancer

作　　者：谭志军[1] 刘玉莹[1] 李昌生[1] 杨彩云[1] Tan Zhijun;Liu Yuying;Li Changsheng;Yang Caiyun(Department of General Surgery, the Shouguang People Hospital, Shouguang 262700, China)

机构地区：[1]寿光市人民医院普外科,262700

出　　处：《中华结直肠疾病电子杂志》2016年第2期153-158,共6页Chinese Journal of Colorectal Diseases(Electronic Edition)

摘　　要：目的研究肿瘤组织内高迁移率蛋白族1(High mobility group box 1,HMGB1)和Bcl-2表达与结直肠癌(CRC)化疗耐药及预后的关系。方法采用免疫组化法分析97名CRC患者肿瘤组织中HMGB1和Bcl-2的表达强度,并分析其与CRC不同临床病理特征、患者总生存期及化疗反应率间的关系。结果中分化、低分化CRC中HMGB1高表达率和Bcl-2阳性表达率显著高正常组织(P<0.05)。HMGB1表达与CRC患者淋巴浸润、脉管浸润及化疗反应率显著相关(P<0.05),与其他临床病理特征及患者总生存期无显著相关性(P>0.05)。Bcl-2表达与患者临床病理特征及总生存期无显著相关性(P>0.05),但与化疗反应率显著相关(P<0.05)。结论 HMGB1高表达和Bcl-2阳性表达可用于预示CRC化疗耐药,HMGB1高表达可作为CRC预后的预测指标。Objective To investigate the impact of HMGB1 expression and Bcl-2 expression onchemo-resistance and prognosis of colorectal cancer (CRC). Method HMGB1 expression and Bcl-2 expressionin CRC tumor tissues from 97 patients was analyzed by immunohistochemistry. Relationship amongHMGB1 high expression, Bcl-2 positive expression, clinical histological features, overall survival andchemotherapy response rate were compared. Results HMGB1 high expression rates and Bcl-2 positiveexpression rates in low differentiated and differentiation CRC specimens were significant higher than thatin high differentiated tissues (P < 0.05). Lymphatic invasion, venous invasion and chemotherapy responserate showed significant correlation with HMGB1 expression (P < 0.05). Chemotherapy response rate wasalso significantly affected by Bcl-2 expression (P < 0.05). Conclusions HMGB1 high expression andBcl-2 positive expression may be used to predict chemo-resistance. HMGB1 high expression may be usedas predictors of CRC prognosis.

关 键 词：结直肠肿瘤 治疗 耐药 预后 

分 类 号：R735.34[医药卫生—肿瘤]